IP Library Granted Patent US 9,662,421
Granted Patent B2
US 9,662,421 · App. 15/169,868 · Granted May 30, 2017

Bioengineered allogeneic blood vessel

Inventors: Suchitra Sumitran-Holgersson (Göteborg, SE); Michael Olausson (Göteborg, SE)
Assignee: NOV AHEP AB
A61L27/507A61L27/24A61L27/3808A61L27/3826A61L27/54C12N5/0691C12N5/0692A61F2/06A61F2/062A61F2240/001A61L2300/252A61L2300/64A61L2430/34C12N2533/54
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,662,421
App. No.
15/169,868
Granted
May 30, 2017
Kind
B2
Abstract

The present invention relates to methods for recellurization of blood vessels. This method is particularly useful for producing an allogeneic vein, wherein a donor vein is decellularized and then recellularized using whole blood or bone marrow stem cells. The allogeneic veins produced by the methods disclosed herein are particularly advantageous for implantation or transplantation into patients with vascular diseases.

Claims (28)

1. A method of preparing a vascular graft comprising introducing whole blood comprising progenitor cells for endothelial or smooth muscle cells to the lumen of a tubular acellular scaffold and culturing said cells, wherein the cultured cells populate the scaffold, thereby preparing the vascular graft.

2. The method of claim 1 , wherein the tubular acellular scaffold comprises collagen I, collagen III, or collagen IV.

3. The method of claim 1 , wherein said introducing the whole blood to the lumen of the tubular acellular scaffold is by injection or perfusion.

4. The method of claim 1 , wherein said culturing comprises perfusion of endothelial cell medium and/or smooth muscle cell medium.

5. The method of claim 4 , wherein said perfusion of said endothelial cell medium and said smooth muscle cell medium are in alternation.

6. The method of claim 5 , wherein said perfusion in alternation is repeated at least twice.

7. The method of claim 1 , wherein said culturing the cells on the lumen of the tubular acellular scaffold results in proliferation and/or differentiation of the cells to endothelial cells and smooth muscle cells.

8. The method of claim 7 , wherein said endothelial cells line the inner lining or the lumen of the tubular acellular scaffold, and said smooth muscle cells migrate to the walls or are present over the middle and outer layers of the tubular acellular scaffold.

9. The method of claim 7 , wherein said endothelial cells express VE-cadherein, AcLDL, vWF or CD31.

10. The method of claim 7 , wherein said smooth muscle cells express smooth muscle actin or vimentin.

11. The method of claim 1 , wherein said culturing the cells is in vitro.

12. The method of claim 1 , wherein the vascular graft is a vein or an artery graft.

13. A method of treating a vascular disease or disorder in a subject in need thereof, comprising providing a vascular graft to the subject, wherein the vascular graft is prepared by a method comprising

a. introducing subject-derived whole blood comprising progenitor cells for endothelial or smooth muscle cells to the lumen of a tubular acellular scaffold; and

b. culturing said cells on the lumen of the tubular acellular scaffold, thereby preparing the vascular graft;

wherein the vascular graft is transplanted to the subject for treating the vascular disease or disorder.

14. The method of claim 13 , wherein the tubular acellular scaffold is a decellularized blood vessel.

15. The method of claim 13 , wherein the tubular acellular scaffold comprises collagen I, collagen III, or collagen IV.

16. The method of claim 13 , wherein said introducing the subject-derived whole blood to the lumen of the tubular acellular scaffold is by injection or perfusion.

17. The method of claim 13 , wherein said culturing comprises perfusion of endothelial cell medium and/or smooth muscle cell medium.

18. The method of claim 17 , wherein said perfusion of said endothelial cell medium and said smooth muscle cell medium are in alternation.

19. The method of claim 18 , wherein said perfusion in alternation is repeated at least twice.

20. The method of claim 13 , wherein said culturing the subject-derived whole blood on the lumen of the tubular acellular scaffold results in proliferation and/or differentiation of the cells to endothelial cells and smooth muscle cells.

21. The method of claim 20 , wherein said endothelial cells line the inner lining or the lumen of the tubular acellular scaffold, and said smooth muscle cells migrate to the walls or are present over the middle and outer layers of the tubular acellular scaffold.

22. The method of claim 20 , wherein said endothelial cells express VE-cadherein, AcLDL, vWF or CD31.

23. The method of claim 20 , wherein said smooth muscle cells express smooth muscle actin or vimentin.

24. The method of claim 13 , wherein said culturing the cells is in vitro.

25. The method of claim 13 , wherein the vascular graft is a vein or an artery graft.

Assignments (3)
NAME CHANGE Recorded Apr 22, 2019
From: NOVAHEP AB
To: VERIGRAFT AB
Reel/Frame 048956/0658 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 23, 2017
From: SUMITRAN-HOLGERSSON, SUCHITRA; OLAUSSON, MICHAEL
To: NOVAHEP AB
Reel/Frame 041046/0150 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 23, 2017
From: NOVAHEP AB
To: OLAUSSON - PARTIAL INTEREST (ENTIRE INTEREST OWNED BY NOVAHEP AB, MICHAEL OLAUSSON), MICHAEL
Reel/Frame 041046/0176 →
Continuity (4)
Continuation 14723727 · May 28, 2015
Continuation 14364756
Provisional Application 61611810 · Mar 16, 2012
Related Publication 20170049935A1 · Feb 23, 2017